Tirapazamine is a bioreductive prodrug that has been investigated as a potential treatment for cancer. It is designed to become activated in the low-oxygen (hypoxic) environments typical of many solid tumors. This selective activation is intended to enhance the drug's efficacy while minimizing damage to healthy, oxygenated tissues.
